Drugs associated with teratogenic mechanisms. Part I: Dispensing rates among pregnant women in the Netherlands, 1998-2009

Human Reproduction

Volumn 29, Issue 1, 2014, Pages 161-167

  Van Gelder, Marleen M H J ^a   Bos, Jens H J ^b   Roeleveld, Nel ^a   De Jong Van Den Berg, Lolkje T W ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Congenital abnormalities; Pharmaceutical agents; Pregnancy; Teratology

Indexed keywords

AMANTADINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; BORIC ACID; BOSENTAN; DEXTROMETHORPHAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETRETINATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; KETAMINE; KETOCONAZOLE; METFORMIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PRESCRIPTION DRUG; PROSTAGLANDIN SYNTHASE INHIBITOR; RISPERIDONE; SALAZOSULFAPYRIDINE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TERATOGENIC AGENT; TERBUTALINE; TETRACYCLINE DERIVATIVE; THALIDOMIDE; TRIMETHOPRIM; UNINDEXED DRUG;

ARTICLE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; OXIDATIVE STRESS; PHARMACY; PREGNANCY; PREGNANT WOMAN; PRESCRIPTION; TERATOGENICITY;

CONGENITAL ABNORMALITIES; PHARMACEUTICAL AGENTS; PREGNANCY; TERATOLOGY;

ABNORMALITIES, DRUG-INDUCED; ADULT; CYCLOOXYGENASE INHIBITORS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; SEROTONIN UPTAKE INHIBITORS; TERATOGENS;

EID: 84890674184     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det369     Document Type: Article

References (24)

1. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011;157:175-182.
2. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
3. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, McPhillips H, Roblin D, Smith DH et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006;15:546-554.
4. BakkerMK, Jentink J, VroomF, VanDenBerg PB, DeWalle HEK, DeJong-Van Den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006;113:559-568.
5. Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010; 19:408-417.
6. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 2010;19:1137-1150.
7. CooperWO, Willy ME, Pont SJ, RayWA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196:544. e1-544. e5.
8. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38:90-96.
9. Hernandez-D?az S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the U. S. population. Environ Health Perspect 2009;117:185-189.
10. Kennedy DS. A to X: the problem of categorisation of drugs in pregnancy-an Australian perspective. Med J Aust 2011;195:572-574.
11. Leufkens HG, Urquhart J. Automated pharmacy records linkage in the Netherlands. In Strom BL (ed) Pharmacoepidemiology, 4th edn. Chichester, UK: JohnWiley & Sons Ltd, 2005, 311-322.
12. Mitchell AA. Systematc identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003;349:2556-2559.
13. Pollard I. Neuropharmacology of drugs and alcohol in mother and fetus. Semin Fetal Neonatal Med 2007;12:106-113.
14. Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf 2005;14:829-836.
15. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edn, 2007. London, UK: Academic Press.
16. Schirm E, Tobi H, de Jong-van den Berg LTW. Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol 2004;57:737-741.
17. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use during pregnancy in Sweden-assessed by the prescribed drug register and the medical birth register. Clin Epidemiol 2011;3:43-50.
18. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL, Sullivan S et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect 2005;113:1056-1061.
19. Thorpe PG, Gilboa SM, Hernandez-Diaz S, Lind J, Cragan JD, Briggs G, Kweder S, Friedman JM, Mitchell AA, Honein MA. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Saf 2013;22:1013-1018.
20. Van Gelder MMHJ, van Rooij IALM, Miller RK, Zielhuis GA, de Jong-van den Berg LTW, Roeleveld N. Teratogenic mechanisms of medical drugs. Hum Reprod Update 2010;16:378-394.
21. Van Gelder MMHJ, de Jong-van den Berg LTW, Roeleveld N. Drugs associated with teratogenic mechanisms. part II: a literature review of the evidence on human risks. Hum Reprod 2014;29:168-183.
22. Van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol 1998;11(Suppl. 1):S13-S19.
23. Visser ST, Schuiling-Veninga CCM, Bos JHJ, de Jong-van den Berg LTW, Postma MJ. The population-based prescription database IADB. nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res 2013;13:285-292.
24. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2010. http://www. whocc. no/atc-ddd-index/ (1 October 2010, date last accessed).